Blog
RSS FeedPosted by Michael Wonder on 03 Nov 2019
International impact of external reference pricing: should national policy makers care?
3 November 2019 - External reference pricing is widely used to regulate drug prices. ...
Posted by Michael Wonder on 26 Oct 2019
Real-time benefit tools for drug prices
25 October 2019 - Concerns over drug prices and medication nonadherence have led to a search for new strategies to lower ...
Posted by Michael Wonder on 21 Oct 2019
International pricing index ‘accomplishes nothing it sets out to do’
21 October 2019 - Even with all of the political chatter in Washington, D.C., talk about controlling prescription drug prices ...
Posted by Michael Wonder on 01 Oct 2019
Variation in prescription drug prices by retail pharmacy type: a national cross-sectional study
1 October 2019 - Cash prices for prescription drugs vary widely in the United States. ...
Posted by Michael Wonder on 12 Aug 2019
New Zealand's access to funded medicines 'well behind the rest of the world'
12 August 2019 - New Zealand has the worst access to funded modern medicines of 20 OECD countries, a report ...
Posted by Michael Wonder on 14 Jul 2019
Bev takes 14 pills a day. She's far from alone.
15 July 2019 - She is among the more than one-in-three Australians aged over 70 who take five or more different ...
Posted by Michael Wonder on 09 Jul 2019
CMS’s international pricing model for Medicare Part B drugs: implementation issues
9 July 2019 - For many years, Americans have paid significantly more than the rest of the world for prescription drugs. ...
Posted by Michael Wonder on 17 Jun 2019
Population adjustment methods for indirect comparisons: A review of NICE Technology Appraisals
13 June 2019 - Indirect comparisons via a common comparator (anchored comparisons) are commonly used in health technology assessment. However, ...
Posted by Michael Wonder on 18 Feb 2019
Hospital drug prices are up to 7 times greater than Medicare pricing
15 February 2019 - A new study shows something many healthcare patients know all too well: hospitals are charging significant ...
Posted by Michael Wonder on 08 Feb 2019
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...
Posted by Michael Wonder on 06 Feb 2019
Comparing PHARMAC's outcomes with those of Australia
7 February 2019 - New Zealand's Prime Minister Jacinda Ahern's claim that is unfair to compare PHARMAC's outcomes with those ...
Posted by Michael Wonder on 05 Feb 2019
Jacinda Ardern: not fair to compare PHARMAC with Australia's system
5 February 2019 - Jacinda Ardern told The AM Show New Zealand's drug buying agency has "been pointed to as being ...
Posted by Michael Wonder on 20 Jan 2019
The U.S. should assess the economic value of drugs rather than leave it up to other countries
17 January 2019 - One reason why prescription drugs are often priced lower overseas is that many countries perform detailed ...
Posted by Michael Wonder on 19 Dec 2018
Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score
19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...
Posted by Michael Wonder on 11 Dec 2018
Dozens of groups attack Trump plan to peg drug prices to what other countries pay
10 December 2018 - A controversial Trump administration plan to lower drug costs by pegging prices to what are paid ...